Phospholipase A2 Receptor Antibody (PLA2R), Quantitative Test
Phospholipase A2 Receptor Antibody (PLA2R), Quantitative Test
The Phospholipase A2 Receptor Antibody (PLA2R), Quantitative Test is used to diagnose and monitor primary membranous nephropathy (PMN), an autoimmune kidney disease that causes proteinuria (excess protein in urine) and can lead to chronic kidney disease (CKD). PLA2R is a transmembrane receptor primarily found in kidney podocytes, and the presence of PLA2R autoantibodies in the blood strongly indicates PMN. Measuring the levels of these antibodies helps determine disease activity, assess response to treatment, and predict the likelihood of disease recurrence after therapy.
Primary membranous nephropathy (PMN) is the most common cause of nephrotic syndrome in adults. It is an autoimmune disorder in which the body's immune system mistakenly targets PLA2R proteins located in the kidney's glomerular basement membrane. This leads to immune complex deposition, thickening of the glomerular capillary walls, and increased permeability, allowing proteins to leak into the urine. Unlike secondary membranous nephropathy, which may be associated with infections, malignancies, systemic autoimmune diseases (such as lupus), or certain medications, PMN occurs without an identifiable secondary cause.
PMN can progress gradually, leading to persistent proteinuria, hypoalbuminemia, hyperlipidemia, and edema. Some patients may experience spontaneous remission, while others progress to end-stage renal disease (ESRD) requiring dialysis or kidney transplantation. Early detection and monitoring with the PLA2R antibody test are crucial in guiding treatment decisions, including the use of immunosuppressive therapies to reduce disease activity and prevent complications.
What is the PLA2R Antibody Test Used For?
This test is essential for:
- Diagnosing primary membranous nephropathy (PMN)
- Differentiating PMN from secondary membranous nephropathy
- Monitoring disease progression and treatment response
- Predicting the likelihood of disease remission or relapse
- Evaluating patients with unexplained proteinuria
Symptoms Indicating the Need for This Test
A PLA2R Antibody Test may be recommended if a patient exhibits
Persistent proteinuria (foamy urine)
Swelling (edema) in the legs, ankles, or around the eyes
Fatigue and unexplained weight gain
High blood pressure (hypertension)
Decreased kidney function or abnormal kidney test results
No clear cause for nephrotic syndrome
Preparation for the Test
No special preparation is required for this test. Patients should inform their doctor about any medications or autoimmune conditions that may influence test results. A blood sample is drawn from a vein in the arm.
Interpretation of Results
- Negative (<2 RU/mL): No detectable PLA2R antibodies, suggesting low likelihood of PMN or remission.
- Low-Positive (2-20 RU/mL): Possible early or resolving PMN; further clinical assessment needed.
- Moderate to High-Positive (>20 RU/mL): Strongly suggests active PMN, with higher values correlating with more severe disease activity.
Note: A decline in PLA2R antibody levels during treatment is a good prognostic indicator, while persistently high levels may indicate continued disease activity or relapse.
FAQs
How is the sample collected for the PLA2R Antibody Test?
A blood sample is drawn from a vein in your arm and analyzed in the laboratory.
How long does it take to get test results?
Results are typically available within 5-7 days, depending on the laboratory.
Can other kidney diseases cause PLA2R antibodies to be present?
PLA2R antibodies are specific to primary membranous nephropathy (PMN) and are not typically found in secondary nephropathy caused by lupus, infections, or medications.
What does a decrease in PLA2R antibody levels mean?
A decrease suggests treatment effectiveness and possible disease remission, while persistent elevation indicates ongoing kidney damage.
What should I do if my PLA2R antibody levels are high?
Consult a nephrologist for further evaluation and possible treatment, including immunosuppressive therapy if necessary.
Related tests
Tests At Lupin Diagnostics